This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of
Exercise has been shown to be beneficial for the management of common adverse effects of cancer and its treatment such as fatigue, anxiety, depression, changes in strength and physical function, and sleep disruption. Get Real and Heel provides participants with the opportunity to obtain these benefits, regardless of cancer type and disease stage, and without cost.
Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal
The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.
Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.
Do you have Leukemia, Lymphoma or any other blood disorder that requires you to have frequent visits to have laboratory tests? You maybe able to participate in a study using a device to help monitor your abnormal blood levels.
In this study, we want to find out if an investigational treatment, P-CD19CD20-ALLO1, is safe and will help treat people with some B-cell malignancies. The study is also being done to determine what dose is tolerated and whether it is effective in treating some B cell malignancies.
We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.
This study enrolling people who recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL). The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics").
We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).